Page last updated: 2024-09-04

sabarubicin and Cancer of Ovary

sabarubicin has been researched along with Cancer of Ovary in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adank, S; Caponigro, F; Capriati, A; Comandini, A; Demol, J; Floquet, A; Sorio, R; Tambaro, R; van Belle, S; Wanders, J; Willemse, P	1
Binaschi, M; Camarda, G; Goso, C; Maggi, CA; Manzini, S; Salvatore, C	1
Animati, F; Arcamone, F; Berettoni, M; Bigioni, M; Capranico, G; Casazza, AM; Caserini, C; Cipollone, A; De Cesare, M; Franciotti, M; Lombardi, P; Madami, A; Manzini, S; Monteagudo, E; Polizzi, D; Pratesi, G; Righetti, SC; Salvatore, C; Supino, R; Zunino, F	1
Bigioni, M; De Cesare, M; Gonzalez-Paz, O; Maggi, CA; Manzini, S; Polizzi, D; Pratesi, G; Zunino, F	1

Trials

1 trial(s) available for sabarubicin and Cancer of Ovary

Article	Year
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Investigational new drugs, 2005, Volume: 23, Issue:1 Topics: Aged; Antineoplastic Agents; Bridged-Ring Compounds; Disaccharides; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Remission Induction; Salvage Therapy; Taxoids	2005

Article

Year

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.

Investigational new drugs, 2005, Volume: 23, Issue:1

Topics: Aged; Antineoplastic Agents; Bridged-Ring Compounds; Disaccharides; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Remission Induction; Salvage Therapy; Taxoids

2005

Other Studies

3 other study(ies) available for sabarubicin and Cancer of Ovary

Article	Year
NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. International journal of oncology, 2005, Volume: 27, Issue:3 Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Cell Survival; Disaccharides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Gene Expression; Humans; Multidrug Resistance-Associated Proteins; NF-kappa B; Nitriles; Ovarian Neoplasms; RNA, Messenger; Signal Transduction; Sulfones; Time Factors; Vinblastine	2005
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Journal of the National Cancer Institute, 1997, Aug-20, Volume: 89, Issue:16 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Small Cell; Disaccharides; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Ovarian Neoplasms; Time Factors; Transplantation, Heterologous	1997
Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Disaccharides; Doxorubicin; Female; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous	2001